XML 81 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Fair Value Disclosures [Abstract]    
Fair Value, by Balance Sheet Grouping [Table Text Block]
The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

 
As of December 31, 2014
 
Fair Value Measurements
 
Carrying
 
Fair
 
As of December 31, 2014
 
Amount
 
Value
 
Level 1
 
Level 2
 
Level 3
Assets:
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
 
 
Cash
$
6,836

 
$
6,836

 
$
6,836

 
$

 
$

Money market funds
16,275

 
16,275

 
16,275

 

 

 
$
23,111

 
$
23,111

 
$
23,111

 
$

 
$

Marketable securities:
 

 
 

 
 

 
 

 
 

Money market funds
$
48

 
$
48

 
$
48

 
$

 
$

Mutual funds
59

 
59

 
59

 

 

U.S. Treasury securities
1,070

 
1,070

 
1,070

 

 

Government agency securities
317

 
317

 
317

 

 

 
$
1,494

 
$
1,494

 
$
1,494

 
$

 
$

Liabilities:
 
 
 
 
 
 
 
 
 
Contingent consideration:
 
 
 
 
 
 
 
 
 
Asuragen
$
4,476

 
$
4,476

 
$

 
$

 
$
4,476

RedPath
22,066

 
22,066

 

 

 
22,066

 
$
26,542

 
$
26,542

 
$

 
$

 
$
26,542



 
As of December 31, 2013
 
Fair Value Measurements
 
Carrying
 
Fair
 
As of December 31, 2013
 
Amount
 
Value
 
Level 1
 
Level 2
 
Level 3
Assets:
 
 
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
 
 
Cash
$
10,315

 
$
10,315

 
$
10,315

 
$

 
$

Money market funds
35,324

 
35,324

 
35,324

 

 

 
$
45,639

 
$
45,639

 
$
45,639

 
$

 
$

Marketable securities:
 

 
 

 
 

 
 

 
 

Money market funds
$
48

 
$
48

 
$
48

 
$

 
$

Mutual funds
55

 
55

 
55

 

 

U.S. Treasury securities
1,730

 
1,730

 
1,730

 

 

Government agency securities
382

 
382

 
382

 

 

 
$
2,215

 
$
2,215

 
$
2,215

 
$

 
$

 
Fair Value Measurements, Nonrecurring [Table Text Block]
The following table summarizes these assets of the Company measured at fair value on a nonrecurring basis as of December 31, 2014:
  
 
 
 
 
Fair Value Measurements as of
 
 
Carrying Amount as of
 
December 31, 2014
 
 
December 31, 2014
 
Level 1
 
Level 2
 
Level 3
Long-lived assets held and used:
 
 
 
 
 
 
 
 
   Thyroid
 
$
522

 
$

 
$

 
$
522

   Pancreas
 
8,519

 

 

 
8,519

   Biobank
 
2,728

 

 

 
2,728

   Pancreas test
 
1,428

 

 

 
1,428

   Barrett's test
 
15,756

 

 

 
15,756

   CLIA lab
 
18,351

 

 

 
18,351

 
 
$
47,304

 
$

 
$

 
$
47,304